Skip to main content
Premium Trial:

Request an Annual Quote

Bob Englert, Steve Crouse

Vortex Biosciences has appointed Bob Englert as its new CEO. Englert, who was previously the firm's chief technology officer, replaces exiting CEO Gene Walther, who has resigned to pursue other interests and will step down both from his position as CEO and as a member of the company's board.

Englert has over 25 years of experience in medical devices and life sciences, with a particular focus on IVD, point of care, and digital health solutions. Before joining Vortex, he served as CEO and founder of Biomedtrics, a diabetes data management company, and prior to that he was COO of Pelikan Technologies. Earlier in his career, Englert also held multiple senior roles at Abbott Laboratories. He holds a BS in biology from the University of Illinois Urbana-Champaign.

Vortex also said that Steve Crouse, who has been the company's chief commercial officer since March 2016, will now assume the position of chief operating officer. Prior to joining Vortex, Crouse served as senior vice president of sales and marketing at Freeslate, a company focused on providing laboratory automation to chemical and pharmaceutical companies.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.